title: Anti-oxidative effect of fluvastatin in hyperlipidemic type 2 diabetic patients.
abstract: An open-label prospective cross-over trial was performed to evaluate the antioxidative effect of fluvastatin in Japanese type 2 diabetics with hyperlipidemia. The study subjects were 10 patients who were on pravastatin (10 mg/day) or simvastatin (5 mg/day). After at least 12 weeks of continuous pravastatin or simvastatin therapy, the drugs were washed out for 12 weeks and replaced with fluvastatin (30 mg/day), then the treatment was continued for another 12 weeks. Total cholesterol and LDL cholesterol were efficiently and comparably reduced by all three statin agents. There were no differences in serum parameters of oxidative stress such as malondialdehyde-modified low-density lipoprotein, thiobarbituric acid-reactive substances, and 8-iso-prostaglandin F2alpha between pravastatin/simvastatin and fluvastatin. However, fluvastatin, but not pravastatin/simvastatin, significantly reduced 3,5,7-cholestatriene in erythrocyte membrane, representing the extent of membrane cholesterol peroxidation. Our data demonstrated that fluvastatin has a unique anti-oxidative effect in patients with type 2 diabetes and hyperlipidemia, compared with other statins.
authors.affiliation: Department of Medicine, Metabolism and Endocrinology, Juntendo University School of Medicine, Hongo, Tokyo, Japan.
authors.forename: Shinnya
authors.initials: S
authors.lastname: Miwa
authors.forename: Hirotaka
authors.initials: H
authors.lastname: Watada
authors.forename: Chie
authors.initials: C
authors.lastname: Omura
authors.forename: Naoko
authors.initials: N
authors.lastname: Takayanagi
authors.forename: Kyoko
authors.initials: K
authors.lastname: Nishiyama
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Tanaka
authors.forename: Tomio
authors.initials: T
authors.lastname: Onuma
authors.forename: Ryuzo
authors.initials: R
authors.lastname: Kawamori
mesh_terms: D000368:Aged; D000975:Antioxidants / Q000627:therapeutic use*; D002782:Cholestenes / Q000097:blood; D002784:Cholesterol / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy; D004910:Erythrocyte Membrane / Q000737:chemistry; D005229:Fatty Acids, Monounsaturated / Q000627:therapeutic use*; D005260:Female; D000077340:Fluvastatin; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006949:Hyperlipidemias / Q000150:complications / Q000188:drug therapy*; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007211:Indoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress; D017035:Pravastatin / Q000627:therapeutic use; D011446:Prospective Studies; D019821:Simvastatin / Q000627:therapeutic use; D017392:Thiobarbituric Acid Reactive Substances / Q000032:analysis
chemical_list: D000975:Antioxidants; D002782:Cholestenes; D002784:Cholesterol; D008078:Cholesterol, LDL; D005229:Fatty Acids, Monounsaturated; D000077340:Fluvastatin; D006442:Glycated Hemoglobin; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007004:Hypoglycemic Agents; D007211:Indoles; D017035:Pravastatin; D019821:Simvastatin; D017392:Thiobarbituric Acid Reactive Substances; C505103:3,5,7-cholestatriene